2',3'-Dideoxyinosine (ddI) is a purine analogue that after intracellular metabolic conversion suppresses the replication of the human immunodeficiency virus (HIV). We conducted a Phase I dose-escalation study of ddI in 17 patients with the acquired immunodeficiency syndrome (AIDS) and 20 patients with AIDS-related complex. The drug was administered twice daily over a dose range of 0.4 to 66 mg per kilogram of body weight per day for 2 to 44 weeks. The maximal tolerated oral dose of ddI was estimated to be 12 mg per kilogram per day. The major dose-limiting toxic effects were a painful peripheral neuropathy (in eight patients) and pancreatitis (in five). Asymptomatic elevations of the serum aminotransferase levels (in 13 patients) and the serum urate level (in 10) were also noted, but there was no dose-related hematologic toxicity. At the maximal tolerated dose, the peak plasma levels of ddI were 6.3 to 9.6 mumol per liter 0.6 to 1 hour after oral administration; the mean plasma half-life was 1.5 hours. The administration of ddI was associated with statistically significant decreases in serum level of p24 antigen and increases in the numbers of CD4 cells at 2, 6, 10, and 20 weeks. These changes were seen at all dose levels studied. Either a clinical improvement or a weight gain of greater than or equal to 2 kg was observed in 25 of 34 patients at six weeks. We conclude that ddI is a promising therapeutic agent in patients with AIDS or AIDS-related complex. Its efficacy is currently being evaluated in large-scale, controlled clinical trials.
Source Information
Department of Medicine, University of Rochester School of Medicine and Dentistry, N.Y. 14642.
This article has been cited by other articles:
Walker, U. A., Tyndall, A., Daikeler, T.
(2008). Rheumatic conditions in human immunodeficiency virus infection. Rheumatology (Oxford)
47: 952-959
[Abstract][Full Text]
Setzer, B., Lebrecht, D., Walker, U. A.
(2008). Pyrimidine Nucleoside Depletion Sensitizes to the Mitochondrial Hepatotoxicity of the Reverse Transcriptase Inhibitor Stavudine. Am. J. Pathol.
172: 681-690
[Abstract][Full Text]
Cherry, C. L., Skolasky, R. L., Lal, L., Creighton, J., Hauer, P., Raman, S. P., Moore, R., Carter, K., Thomas, D., Ebenezer, G. J., Wesselingh, S. L., McArthur, J. C.
(2006). Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology
66: 867-873
[Abstract][Full Text]
Abreu, T., Plaisance, K., Rexroad, V., Nogueira, S., Oliveira, R. H., Evangelista, L. A., Rangel, R., Silva, I. S., Knupp, C., Lambert, J. S.
(2000). Bioavailability of Once- and Twice-Daily Regimens of Didanosine in Human Immunodeficiency Virus-Infected Children. Antimicrob. Agents Chemother.
44: 1375-1376
[Abstract][Full Text]
Berger, A. R., Schaumburg, H. H., Gourevitch, M. N., Freeman, K., Herskovitz, S., Arezzo, J. C.
(1999). Prevalence of peripheral neuropathy in injection drug users. Neurology
53: 592-592
[Abstract][Full Text]
Chang, M., Sood, V. K., Kloosterman, D. A., Hauer, M. J., Fagerness, P. E., Sanders, P. E., Vrbanac, J. J.
(1997). Identification of the Metabolites of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine in Monkeys. Drug Metab. Dispos.
25: 814-827
[Abstract][Full Text]
Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Zhang, W., Branstetter, D. G.
(1997). Metabolism of the HIV-1 Reverse Transcriptase Inhibitor Delavirdine In Mice. Drug Metab. Dispos.
25: 828-839
[Abstract][Full Text]
Cui, L., Locatelli, L., Xie, M.-Y., Sommadossi, J.-P.
(1997). Effect of Nucleoside Analogs on Neurite Regeneration and Mitochondrial DNA Synthesis in PC-12 Cells. J. Pharmacol. Exp. Ther.
280: 1228-1234
[Abstract][Full Text]
Chang, M., Sood, V. K., Wilson, G. J., Kloosterman, D. A., Sanders, P. E., Hauer, M. J., Fagerness, P. E.
(1997). Metabolism of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Delavirdine in Rats. Drug Metab. Dispos.
25: 228-242
[Abstract][Full Text]
Dolin, R., Amato, D. A., Fischl, M. A., Pettinelli, C., Beltangady, M., Liou, S.-h., Brown, M. J., Cross, A. P., Hirsch, M. S., Hardy, W. D., Mildvan, D., Blair, D. C., Powderly, W. G., Para, M. F., Fife, K. H., Steigbigel, R. T., Smaldone, L., AIDS Clinical Trials Group, , National Institute of Allergy and Infectious Disea, , National Institutes of Health, , Bristol-Myers Squibb, , Crumpacker, C. S., Cooley, T., Mitsuyaso, R. T., John, R., Sanders, C., Reitman, D., Hewitt, R., Reichman, R. C., Gelb, L. D., McGuire, M. L., Jones, M., Neidig, J. L., Zwickl, B., Hartman, P. B., Roarke, M. E., Burk, R. A., Fuhrer, J., Somogyi, K. A., Sepkowitz, K., Telzak, E. E., McAuliffe, V. J., Valentine, F. T., Vasquez, M., Merigan, T. C., Katzenstein, D., Fessell, J., Havlir, D. V., Richman, D. D., Spector, S. A., Kahn, J. O., Johnson, L., Coleman, R., Ho, M., McMahon, D., Pazin, G., Antoniskis, D., McNamara, B., Diamond, D., Collier, A. C., Paradise, M. A., Wald, A., DePaolis-Jones, A., Henry, K., Waskin, H. A., Hyslop, N. E. Jr, Mushatt, D. M., Zachary, J. A., Soeiro, R., Harris, C., Zingman, B., Giordano, M. F., Sledz, S., Murray, H. W., Carey, J. T., Davis, T. L., Bagby, B., Kessler, H. A., Murphy, R. I., Hirschtick, R. E., Cheeseman, S. H., Lai, K. K., Fairchild, P. G., Ehmann, W. C., Zurlo, J. J., Millard, R., Troiani, L., Heggen, A. A., van der Horst, C. M., McKinley, G. F., Grieco, M. H., Kolatch, B. R., Goldsmith, J. C., Gomperts, E. D., Woods, L. M., Grue, L., Mayjo, K., Becker, R. L., Jayaweera, D. T., Rolfe, L., Cole, J., Jermano, J.
(1995). Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine. Arch Intern Med
155: 961-974
[Abstract]
Whitcup, S. M., Dastgheib, K., Nussenblatt, R. B., Walton, R. C., Pizzo, P. A., Chan, C.-C.
(1994). A Clinicopathologic Report of the Retinal Lesions Associated With Didanosine. Arch Ophthalmol
112: 1594-1598
[Abstract]
Abrams, D. I., Goldman, A. I., Launer, C., Korvick, J. A., Neaton, J. D., Crane, L. R., Grodesky, M., Wakefield, S., Muth, K., Kornegay, S., Cohn, D. L., Harris, A., Luskin-Hawk, R., Markowitz, N., Sampson, J. H., Thompson, M., Deyton, L., The Terry Beirn Community Programs for Clinical Re,
(1994). A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection. NEJM
330: 657-662
[Abstract][Full Text]
Saag, M. S., Emini, E. A., Laskin, O. L., Douglas, J., Lapidus, W. I., Schleif, W. A., Whitley, R. J., Hildebrand, C., Byrnes, V. W., Kappes, J. C., Anderson, K. W., Massari, F. E., Shaw, G. M., The 661 Working Group L-697,
(1993). A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse Transcriptase. NEJM
329: 1065-1072
[Abstract][Full Text]
Gerber, A. R., Valdiserri, R. O., Holtgrave, D. R., Jones, T. S., West, G. R., Hinman, A. R., Curran, J. W.
(1993). Preventive Services Guidelines for Primary Care Clinicians Caring for Adults and Adolescents Infected With the Human Immunodeficiency Virus. Arch Fam Med
2: 969-979
[Abstract]
Hirsch, M. S., D'Aquila, R. T.
(1993). Therapy for Human Immunodeficiency Virus Infection. NEJM
328: 1686-1695
[Full Text]
McLeod, G. X., Hammer, S. M.
(1992). Zidovudine: Five Years Later. ANN INTERN MED
117: 487-501
[Abstract]
Drusano, G. L., Yuen, G. J., Lambert, J. S., Seidlin, M., Dolin, R., Valentine, F. T.
(1992). Relationship between Dideoxyinosine Exposure, CD4 Counts, and p24 Antigen Levels in Human Immunodeficiency Virus Infection: A Phase I Trial. ANN INTERN MED
116: 562-566
[Abstract]
Sachs, M. K.
(1992). Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine. Arch Intern Med
152: 485-501
[Abstract]
Davis, J. M., Demling, R. H., Lewis, F. R., Hoover, E., Waymack, J. P.
(1992). The Surgical Infection Society's Policy on Human Immunodeficiency Virus and Hepatitis B and C Infection: The Ad Hoc Committee on Acquired Immunodeficiency Syndrome and Hepatitis. Arch Surg
127: 218-221
[Abstract]
Wachtel, T., Piette, J., Mor, V., Stein, M., Fleishman, J., Carpenter, C.
(1992). Quality of Life in Persons with Human Immunodeficiency Virus Infection: Measurement by the Medical Outcomes Study Instrument. ANN INTERN MED
116: 129-137
[Abstract]
Fauci, A. S.
(1992). Combination Therapy for HIV Infection: Getting Closer. ANN INTERN MED
116: 85-86
[Abstract]
McPherson, M. L.
(1991). Management of AIDS and infectious complications. Home Health Care Management Practice
3: 17-24
[Abstract]
Mitsuya, H, Yarchoan, R, Broder, S
(1990). Molecular targets for AIDS therapy. Science
249: 1533-1544
[Abstract]
(1990). DDI FOR AIDS/ARC: PRELIMINARY RESULTS ARE ENCOURAGING. JWatch General
1990: 4-4
[Full Text]
